Illumina Inc. faces a battle to save its $8 billion bid for cancer-test provider Grail from a European Union veto ahead of a Friday deadline to allay antitrust concerns.
EU officials are currently leaning toward blocking the deal by a March 4 deadline, according to people familiar with the review who asked not to be identified because a decision isn’t final. Illumina could still win over regulators by making acceptable concessions by Jan. 28.
